MAGNIFI-CD has improved operating characteristics compared to other indices assessing MRI scans of perianal fistula activity in CD, and that the new index may be useful as an outcome measure in clinical trials investigating treatment for perianal fistulizing CD.
These findings indicate the importance of optimizing infliximab dosage to a level that achieves efficacy without activating an immune response against the infliximab-TNF complex.
The risk for type 2 diabetes was significantly higher for patients who received a diagnosis of IBD from 2003 through 2014 versus those diagnosed from 1977 through 1988 or from 1989 through 2002 (SIRs, 1.79 versus 1.47 and 1.48, respectively).
The association between disease activity and emotional processing biases may play a role in the higher rates of depression in patients with inflammatory bowel disease.
Risk significantly increased for suicide attempt and mood, anxiety, personality, eating disorders.
In terms of benefit and risk, biologics were both considered more beneficial and riskier than immunomodulators. Bowel resection was considered to be slightly more risky, but more beneficial than biologic treatment.
Crohn disease and ulcerative colitis comprise the 2 primary subtypes of inflammatory bowel diseases (IBD). IBD currently has no known cure and whose pathogenesis is not well understood. However, an increasing amount of research points to genetic risk factors combined with antibiotic use and changes in intestinal microbiota as triggers for the onset of IBD.1,2…
Two-part guideline addresses diagnosis, evaluation, management of the chronic inflammatory skin disease
Results provide meaningful information for clinicians to appropriately council patients on expected weight gain after starting infliximab therapy.
Vedolizumab has demonstrated efficacy among individuals with moderate to severe active Crohn disease, according to a study recently published in Gastroenterology. Improvements were observed in radiologic, histologic, and endoscopic outcomes. This open-label, phase-3b trial (VERSIFY; ClinicalTrials.gov identifier: NCT02425111) included 101 individuals who had experienced active Crohn disease for 3 months or more between March 2015…
JAK inhibitors effectively induce clinical remission in patients with Crohn disease and clinical and endoscopic remission in patients with ulcerative colitis.
An update to the American College of Gastroenterology guideline may promote use of more precise diagnostic tools and evidence-based treatments and may enhance health outcomes for patients with Crohn disease.
The aim of this Danish population-based study was to determine the association between anti-TNFα therapy and the risk of developing CD and UC.
A meta-analysis of 13 randomized controlled trials found no association betweendipeptidyl peptidase-4 inhibitor use and inflammatory bowel disease risk in patients with type 2 diabetes.
Treatment with anti-TNFα agents for conditions other than inflammatory bowel disease may increase the risk of developing Crohn disease or ulcerative colitis.